English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i‐ IFTA ) and its relationship to T cell–mediated rejection ( TCMR ), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody‐mediated rejection ( ABMR ). In confirmation of previous studies, it was independently demonstrated by 2 groups that i‐ IFTA  is associated with reduced graft survival. Furthermore, these groups presented that i‐ IFTA , particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute  TCMR  in association with underimmunosuppression. The classification was thus revised to include moderate i‐ IFTA  plus moderate or severe tubulitis as diagnostic of chronic active  TCMR . Other studies demonstrated that certain molecular classifiers improve diagnosis of  ABMR  beyond what is possible with histology, C4d, and detection of donor‐specific antibodies ( DSAs ) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to  DSAs  in the diagnosis of  ABMR . The Banff  ABMR  criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.

american journal of transplantation

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials